Company Overview and News

1
CatchMark Timber: Asset Sales Propping Up Unsustainable EBITDA And Dividend; 60-100% Downside

4h seekingalpha
We believe investors perceive CatchMark Timber as a defensible REIT with a safe dividend that is funded primarily via the harvest and sale of timber.
CTT LAND DEL POPE CFPZF PTF PHALF LANDP

4
CANADA STOCKS-TSX pushed higher by materials, healthcare stocks

2018-09-19 reuters - 1
Sept 19 (Reuters) - Canada’s main stock index gained ground on Wednesday as the materials group got a boost from higher gold prices and as the healthcare sector rose, led by cannabis producers.
ACB CP CP IFSPF WEED ACBFF CFPZF CGC

1
Canfor Corp. (CFPZF) CEO Donald Kayne on Q2 2018 Results - Earnings Call Transcript

2018-07-28 seekingalpha - 1
Good morning, ladies and gentlemen. Welcome to the Canfor and Canfor Pulp Second Quarter Analyst Call. A recording and transcript of the call will be available on Canfor's website. During this call, Canfor and Canfor Pulp's Chief Financial Officer will be referring to a slide presentation that is available in the Investor Relations section of each company's website. Also, the companies would like to point out that this call will include forward-looking statements so please refer to the press releases for the associated risk of such statements.
CFPUF CFPZF CFX

3
CANADA STOCKS-TSX dips as oil hits energy stocks; Nevsun Resources lifts materials

2018-07-17 reuters
(Reuters) - Canada’s main stock index edged lower on Tuesday as oil prices hovered near their lowest in three months and weighed on energy companies.
NSU FR ACB LUNMF APH CNQ ACBFF LUNCF AG APHQF CFPZF LUN

 
Lumber prices catch fire as tight supply meets trade tariffs

2018-05-16 msn
The lumber market is red-hot, with futures rising to another record on Tuesday thanks to a confluence of import tariffs, transport bottlenecks and strong housing demand.
IFSPF CFPZF

39
Overwhelmed railroads threaten Canadian export economy

2018-05-08 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
CP CVE RDSB ENB RDSA CP KMI EBBNF RYDAF KMR CVB ENBBF TRP RDS.B RDS.A ENB RYDBF CVE NTR STOHF CFPZF KMRFZ STO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 00B18P4F6